The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
10.11005/jbm.2022.29.4.217
- Author:
Arthur Costa INOJOSA
1
;
Laís MENDES
;
Leonardo BANDEIRA
;
Francisco BANDEIRA
Author Information
1. Division of Endocrinology, Agamenon Magalhães Hospital, University of Pernambuco Medical School, Recife, Brazil
- Publication Type:Review Article
- From:Journal of Bone Metabolism
2022;29(4):217-223
- CountryRepublic of Korea
- Language:English
-
Abstract:
Denosumab is a potent anti-resorptive medication used to treat patients at high risk for osteoporosis; however, its beneficial effects on the skeletal system are quickly reversed after discontinuation. In contrast, bisphosphonates (BPs) are anti-resorptive agents with residual effects on the bone matrix; thus, these are capable of preserving bone mass for a long time. Therefore, subsequent anti-resorptive treatment with BPs is mandatory to prevent rebound fractures. Furthermore, BP administration before denosumab treatment appears to be a reasonable strategy for reducing hyperactivation of bone remodeling. In this review, we summarize the effects of BP administration before denosumab treatment in preventing rebound fractures after denosumab discontinuation.
